Afatinib (BIBW2992)

Catalog No.S1011

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Cited by 35 publications:

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nUd2lEPTB;MD6wNFU4OiEQvF2=MVrTRW5ITVJ?
KASUMI-1NYnYfo92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHX5Vo9KSzVyPUCuNFA6OTFizszNNYnkSFJiW0GQR1XS
HCC2218MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HlcGlEPTB;MD6wNFk5PyEQvF2=MkDBV2FPT0WU
KARPAS-45M4DEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HZO2lEPTB;MD6wNVY4OSEQvF2=MYTTRW5ITVJ?
HSC-4M1n4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3oOml[UUN3ME2wMlAyPzR6IN88US=>NXTtNmZHW0GQR1XS
CHL-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXubopKSzVyPUCuNFE5OzlizszNNY\4c5NoW0GQR1XS
KY821MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4G3fGlEPTB;MD6wNlA3KM7:TR?=M1jseXNCVkeHUh?=
NCI-N87M1nHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHiyZ2RKSzVyPUCuNFI4PzNizszNNEe2W|RUSU6JRWK=
DOKM3XCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXIPFlKSzVyPUCuNFMyQTRizszNMlHJV2FPT0WU
DSH1NIC5PVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\DfoNEUUN3ME2wMlA{OzF2IN88US=>M{XrZ3NCVkeHUh?=
MDA-MB-175-VIIM1XkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTBwMEO0NVYh|ryPM1u3RXNCVkeHUh?=
NCI-H2170M1HNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPze|lYUUN3ME2wMlA{PzJ6IN88US=>NGP5Rm5USU6JRWK=
BT-474NGW4fpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvJUFhKSzVyPUCuNFQ6QDZizszNNWnvdFlbW0GQR1XS
EFO-27NYr0O5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTYXnR{UUN3ME2wMlA2OTh{IN88US=>MX;TRW5ITVJ?
NCI-H720MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTBwMEWzNlUh|ryPMUXTRW5ITVJ?
PC-14M3zGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTCUXFwUUN3ME2wMlA2PjZ6IN88US=>MWXTRW5ITVJ?
EC-GI-10M3Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorMTWM2OD1yLkC1PVEzKM7:TR?=NGjSbHJUSU6JRWK=
KYSE-450NX\YcIhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK2VGZKSzVyPUCuNFU6PzhizszNMUPTRW5ITVJ?
BPH-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\2dmlEPTB;MD6wOVk5QCEQvF2=M{T1fnNCVkeHUh?=
NCI-H292NY\5SGRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTBwME[wPUDPxE1?NU\FZZN2W0GQR1XS
H9NWn0bJNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH74UW9KSzVyPUCuNFcyOzJizszNNEHqfWNUSU6JRWK=
NCI-H526MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwMEe4NlMh|ryPMkPNV2FPT0WU
NCI-H1623MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnq3TWM2OD1yLkC4NFI2KM7:TR?=MXzTRW5ITVJ?
KYSE-140NHHRb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fiRmlEPTB;MD6wPFM{KM7:TR?=NXfzcYRDW0GQR1XS
Ca9-22NITnR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7KVppsUUN3ME2wMlA5OzV|IN88US=>M2XuPHNCVkeHUh?=
AU565NXrCc29nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH2wOmhKSzVyPUCuNFg2ODRizszNMkTyV2FPT0WU
ZR-75-30NUHOXJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwMEm1OFUh|ryPNUKzW49RW0GQR1XS
NCI-H1770NHz1cpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTBwMUCyPEDPxE1?M{Tnd3NCVkeHUh?=
LB2241-RCCMmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoKzTWM2OD1yLkGwPFg1KM7:TR?=M3;BenNCVkeHUh?=
CAL-39MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LPfGlEPTB;MD6xNVc6OiEQvF2=M3uwXHNCVkeHUh?=
UACC-893M1LzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFG0dmpKSzVyPUCuNVE5QDVizszNNUO3RYFlW0GQR1XS
LU-65NHO3NItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjCW2Q2UUN3ME2wMlEzPjN|IN88US=>M2[0dHNCVkeHUh?=
HNNHnxUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4n6VWlEPTB;MD6xN|A4PyEQvF2=MXLTRW5ITVJ?
TI-73NIniOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVe1NmozUUN3ME2wMlE1PzF3IN88US=>NVnJUmN[W0GQR1XS
KU812MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3tTWM2OD1yLkG1OFU3KM7:TR?=MYXTRW5ITVJ?
SW13M1LBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmD3TWM2OD1yLkG2NlE3KM7:TR?=NETOPFRUSU6JRWK=
BB30-HNCM1O4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjBXJZKSzVyPUCuNVY2PzZizszNMojSV2FPT0WU
HSC-2NFvCbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTBwMU[4N|ch|ryPNX;XcIhtW0GQR1XS
BV-173MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7ZSJdKSzVyPUCuNVc2QTZizszNMXfTRW5ITVJ?
CAL-27MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTBwMUe2N|Yh|ryPNUHZRVVGW0GQR1XS
SBC-1M1TaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\YUmlEPTB;MD6xPFk2QSEQvF2=MUfTRW5ITVJ?
CAL-33NI\GfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTBwMkCxPFQh|ryPMXrTRW5ITVJ?
NCI-H209M3e0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrCRmhKSzVyPUCuNlA1PiEQvF2=MmPRV2FPT0WU
COR-L105Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XETmlEPTB;MD6yNVA5PCEQvF2=M4X1SHNCVkeHUh?=
HSC-3MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWr0SndYUUN3ME2wMlIyOTl6IN88US=>M3ziPHNCVkeHUh?=
NCI-H69M1nsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknaTWM2OD1yLkKxOFUyKM7:TR?=MUDTRW5ITVJ?
MOLT-13MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PFPWlEPTB;MD6yN|k4PSEQvF2=NX20cWRxW0GQR1XS
ML-2MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTBwMkS4NFIh|ryPMWHTRW5ITVJ?
IGROV-1M3n4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmixTWM2OD1yLkK1PVUzKM7:TR?=NGTxU|BUSU6JRWK=
TK10NEi0XY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jCUGlEPTB;MD6yOlc{QCEQvF2=NFG2OnpUSU6JRWK=
EoL-1-cellM4XXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTLN2JnUUN3ME2wMlI3QDl{IN88US=>NET2SGxUSU6JRWK=
HO-1-N-1MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTBwMke4OVMh|ryPM3i0dHNCVkeHUh?=
BHYMkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2n4fmlEPTB;MD6yPFY2PSEQvF2=NWrLVmJUW0GQR1XS
LU-139M{\VeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;GTWM2OD1yLkOwOVEh|ryPMmfIV2FPT0WU
23132-87MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTBwM{G5NlMh|ryPNFXzO3hUSU6JRWK=
ACHNNWezO4o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rWZ2lEPTB;MD6zNVk6PCEQvF2=MYXTRW5ITVJ?
DoTc2-4510NVTQ[|hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fPXmlEPTB;MD6zNlIyQSEQvF2=MUjTRW5ITVJ?
BB65-RCCNWS1fGlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\uUJMyUUN3ME2wMlM1PTl|IN88US=>MkjNV2FPT0WU
HLEM3j0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTINWN5UUN3ME2wMlM2ODR4IN88US=>NHfUWnFUSU6JRWK=
HCC1419M4nEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXqR3RKSzVyPUCuN|Y1ODhizszNMlPHV2FPT0WU
A388MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nGemlEPTB;MD6zOlg2PyEQvF2=MlP1V2FPT0WU
NUGC-3MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2joVGlEPTB;MD6zPFM4OyEQvF2=MXvTRW5ITVJ?
KYSE-180MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYSxd49MUUN3ME2wMlM6ODh7IN88US=>M{DwNHNCVkeHUh?=
TE-6M1XyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoD6TWM2OD1yLkSwNlQ3KM7:TR?=M4\t[HNCVkeHUh?=
A498NFPNRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\wb2lEPTB;MD60NFY4PCEQvF2=NFq2SZdUSU6JRWK=
NCI-H1648NVviWlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPKcmFKSzVyPUCuOFQyQDJizszNMWnTRW5ITVJ?
DU-145M{TDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwNES4N|Mh|ryPMlnjV2FPT0WU
CW-2NYHRcmFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEn3RWxKSzVyPUCuOFY6OTRizszNM3jW[nNCVkeHUh?=
A431MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTBwNEiyN|Mh|ryPNGfGZ|VUSU6JRWK=
SASM1rnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjHTWM2OD1yLkS4N|k5KM7:TR?=M2SzbnNCVkeHUh?=
NCI-H2126M3Hsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmCzTWM2OD1yLkWxPVI3KM7:TR?=NELJNFhUSU6JRWK=
NCI-H358NUXCUJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIK0UnFKSzVyPUCuOVMzOSEQvF2=MYXTRW5ITVJ?
FADUNWDVcJN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLYXW5PUUN3ME2wMlU1PDB2IN88US=>MX7TRW5ITVJ?
ACNMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH0TWM2OD1yLkW1NFk1KM7:TR?=NX32O|V5W0GQR1XS
HCC70MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTBwNUe2OlEh|ryPMV7TRW5ITVJ?
NCI-H1838NHTkfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2j1[mlEPTB;MD62NFI6QSEQvF2=MV\TRW5ITVJ?
CAL-54NV7sSXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\tRWlEPTB;MD62NVYzOSEQvF2=MX7TRW5ITVJ?
NCI-H1975M4HnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTBwNkG3Nlgh|ryPMnnwV2FPT0WU
COR-L88NXLCZnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzheJE1UUN3ME2wMlY1OTF|IN88US=>M1PSfnNCVkeHUh?=
CTV-1NUHZb4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFOzN3dKSzVyPUCuOlQ{QTJizszNMmLUV2FPT0WU
EW-18MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTPTIdKSzVyPUCuOlg3QThizszNM4Pyd3NCVkeHUh?=
HCC1806NFLyXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTBwNkm2OlYh|ryPMUnTRW5ITVJ?
HuP-T4M2Tq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3MZlhjUUN3ME2wMlY6PzZizszNNIi4PWlUSU6JRWK=
MDA-MB-361MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW[xc5Q5UUN3ME2wMlczPjZ{IN88US=>M1XLenNCVkeHUh?=
NCI-H1573MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnoRmR7UUN3ME2wMlc{PjNizszNNIXMdZBUSU6JRWK=
KU-19-19M33Zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPqfY5KSzVyPUCuO|c1PjRizszNNX7XWmF2W0GQR1XS
COLO-678M37JNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTBwOEC4N|Qh|ryPNHe3Rm5USU6JRWK=
C-33-AMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjJWWFKSzVyPUCuPFEzQTdizszNM1PadXNCVkeHUh?=
Calu-3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDwVGg1UUN3ME2wMlgyPDN2IN88US=>NH7UbpJUSU6JRWK=
AGSMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTBwOEO2OFgh|ryPNWXqeVhjW0GQR1XS
SCC-25NF3KSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTmTWM2OD1yLki0NVcyKM7:TR?=NITlZ4dUSU6JRWK=
JVM-2MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVr6Ro5zUUN3ME2wMlg5Ojl7IN88US=>NHWyW2pUSU6JRWK=
HCE-TMke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnTdYJQUUN3ME2wMlg5PDJ6IN88US=>NFzrTZBUSU6JRWK=
ES4M33QXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF6yVGNKSzVyPUCuPVc5OzZizszNM4nhbHNCVkeHUh?=
EKVXNVXYbHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrvdZB4UUN3ME2xMlAyODZ2IN88US=>Mnm4V2FPT0WU
D-542MGNULtfZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTFwMEGwOlQh|ryPM{PHb3NCVkeHUh?=
SW1116NX\1fo5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHH0So1KSzVyPUGuNFEzQDdizszNNInOVIdUSU6JRWK=
5637M3q1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfuTWM2OD1zLkCxOVEh|ryPNH62VohUSU6JRWK=
HT-1376NXL0XFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;vRmlEPTB;MT6wNVUyOyEQvF2=MnP3V2FPT0WU
NB69MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHOO4o6UUN3ME2xMlAzQTR3IN88US=>M3TBcHNCVkeHUh?=
YKG-1NVfFW5R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHMWYV1UUN3ME2xMlA2PDF7IN88US=>MULTRW5ITVJ?
EW-3MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDTfY9VUUN3ME2xMlA4QDh|IN88US=>NWnqZYRiW0GQR1XS
GCIYNYL2OJA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LxeWlEPTB;MT6wPFExPCEQvF2=M1v6dHNCVkeHUh?=
SK-MES-1NVrFUG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PqfGlEPTB;MT6xNVQ5PyEQvF2=NUT1fVZ2W0GQR1XS
PANC-08-13M3nqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFwMU[0NVYh|ryPNHq4WYZUSU6JRWK=
SK-NEP-1MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\tUmlEPTB;MT6xO|UyOyEQvF2=NEK5c2FUSU6JRWK=
SW954M1PHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfsXm1yUUN3ME2xMlIxOjF2IN88US=>MV7TRW5ITVJ?
NCI-SNU-5NWrNe4poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHiNIxKSzVyPUGuNlM6KM7:TR?=NYLUenJIW0GQR1XS
SW48Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfLS2RKSzVyPUGuNlU1OzJizszNMl3RV2FPT0WU
HT-3NXzRTnV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTFwMki3OVMh|ryPMmn6V2FPT0WU
ETK-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTEOmVDUUN3ME2xMlM4PDV4IN88US=>MnLNV2FPT0WU
SCC-15M2O3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTFwM{m0OVEh|ryPM3XZTXNCVkeHUh?=
DU-4475NWL2U|dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLFTWM2OD1zLkSwNVIyKM7:TR?=MX;TRW5ITVJ?
NB5MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;1TWM2OD1zLkSxN|E4KM7:TR?=NWXhRmJRW0GQR1XS
CFPAC-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTFwNEK0PVMh|ryPMX3TRW5ITVJ?
NCI-H630NUTRWlA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTFwNEW1PFIh|ryPNGnUbpVUSU6JRWK=
NCI-H82MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7aT3VUUUN3ME2xMlU1ODB4IN88US=>MoG4V2FPT0WU
ECC10M{fXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYr3THNzUUN3ME2xMlU2OzZ7IN88US=>NE\PcINUSU6JRWK=
K5M1jZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLTTWM2OD1zLkW4N|U4KM7:TR?=M2n4eXNCVkeHUh?=
ME-180NWjadWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3tPYlKSzVyPUGuOlExQTZizszNMn74V2FPT0WU
KYSE-410NUe2bmtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\GR2lEPTB;MT62OVY4OiEQvF2=MnPhV2FPT0WU
G-401MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7PTWM2OD1zLk[3OFE{KM7:TR?=NHPvPJZUSU6JRWK=
TGBC24TKBNED0empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTFwNkiyN{DPxE1?MWrTRW5ITVJ?
Detroit562NFuxNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELVdGRKSzVyPUGuO|AyPTJizszNMUjTRW5ITVJ?
OE19NF34UINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zGZmlEPTB;MT63NVUyOiEQvF2=NELzZ|RUSU6JRWK=
CAKI-1NGP0UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DKV2lEPTB;MT63PFIyOSEQvF2=MWDTRW5ITVJ?
TE-12MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTFwOEC0NVQh|ryPNFjx[mVUSU6JRWK=
NCI-H1666M3\1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorDTWM2OD1zLkiwPVQ5KM7:TR?=MYLTRW5ITVJ?
TE-1NEDZXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfpfIxKSzVyPUGuPFE1PzVizszNMk\IV2FPT0WU
CAL-12TMlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHiNlRNUUN3ME2xMlg5QTR3IN88US=>MmXEV2FPT0WU
TE-8MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\FSI8zUUN3ME2xMlkyOzd5IN88US=>M2\DOnNCVkeHUh?=
KYSE-270NGnaSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfPeo9KSzVyPUKuNFI4OzJizszNNHzOPWpUSU6JRWK=
GMS-10M37GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJwMEO1NVch|ryPMnTqV2FPT0WU
A2780NXTHV5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPMXGxGUUN3ME2yMlA3Ojl2IN88US=>NXva[4d5W0GQR1XS
OMC-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPITWM2OD1{LkC4NVY6KM7:TR?=M{W4T3NCVkeHUh?=
LoVoNF3TUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PvcGlEPTB;Mj6xNFc6PyEQvF2=NIC1XWdUSU6JRWK=
PANC-03-27NUnrS5J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHHVm5KSzVyPUKuNVY3OzFizszNNF\BTIxUSU6JRWK=
MDA-MB-157MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jjSGlEPTB;Mj6yNVgzQCEQvF2=NGLMTY5USU6JRWK=
CaR-1Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJwMkiyPFEh|ryPM{f2OnNCVkeHUh?=
769-PNFnvemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTJwMkmwN|ch|ryPM133XHNCVkeHUh?=
NB7MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDvfoM{UUN3ME2yMlI6Pjd4IN88US=>MoHkV2FPT0WU
MKN7NV;iWop5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLDS2ZKSzVyPUKuN|U{OzVizszNMWDTRW5ITVJ?
NCI-H1048MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTJwNEmxOVgh|ryPMl3QV2FPT0WU
RCM-1M1\JPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJwNUK5N|gh|ryPMWXTRW5ITVJ?
HT55M1roZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3oTWM2OD1{LkW3N|gh|ryPNIPqUG5USU6JRWK=
HCC1569NXjicJRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFT0O3dKSzVyPUKuOVgzQTdizszNNIq3fIFUSU6JRWK=
LXF-289MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnzTWM2OD1{Lk[zOVY2KM7:TR?=NEnV[25USU6JRWK=
OVCAR-3MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTJwNkexOlch|ryPM1jUOHNCVkeHUh?=
TE-10NEPMcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDTVmxKSzVyPUKuOlgxPzhizszNM2rqbHNCVkeHUh?=
SNU-C2BM3W4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXKU2F4UUN3ME2yMlY5PjF4IN88US=>NXuxV5pbW0GQR1XS
LB1047-RCCMk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{mxV2lEPTB;Mj63OFg5QCEQvF2=MYXTRW5ITVJ?
SN12CNInZNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfXdYFKSzVyPUKuPVE6PjRizszNNHXW[|VUSU6JRWK=
786-0MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrXSWxKSzVyPUOuNFY1ODhizszNMVXTRW5ITVJ?
HT-29M1\xOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETuWWpKSzVyPUOuNFc{ODlizszNM{TkVHNCVkeHUh?=
RPMI-7951NIfsb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjJfYVKSzVyPUOuNFc2QSEQvF2=M3PYd3NCVkeHUh?=
NBsusSRNX24eFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTNwMUiyOVQh|ryPMUHTRW5ITVJ?
NKM-1NWfSS4NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfJe5VtUUN3ME2zMlE5PzR2IN88US=>M4DrUXNCVkeHUh?=
Capan-2NYjrfpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTNwNE[4O|Uh|ryPMWPTRW5ITVJ?
MKN1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDZfZpsUUN3ME2zMlQ4OTB6IN88US=>NFe0bY9USU6JRWK=
OAW-42MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTNwNUCwNlYh|ryPMkjIV2FPT0WU
SKG-IIIaNF3uUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTuTWM2OD1|LkWyNlM4KM7:TR?=MYXTRW5ITVJ?
no-11NXzoUG5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrWfWdKSzVyPUOuOVM2PjRizszNNFKzN4FUSU6JRWK=
NYMk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTNwNUO2OVUh|ryPM17EZ3NCVkeHUh?=
HEC-1MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nXeWlEPTB;Mz61PFk2KM7:TR?=M2P3OXNCVkeHUh?=
NCI-H441M2fm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mor3TWM2OD1|LkW5PFQyKM7:TR?=MnXwV2FPT0WU
NCI-H2009NVfzS2Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zVTWlEPTB;Mz62NVIyPiEQvF2=MUPTRW5ITVJ?
T47DM1XGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4npTGlEPTB;Mz62NlIyPyEQvF2=MUXTRW5ITVJ?
SNU-449MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDGUmhEUUN3ME2zMlY2QDJ4IN88US=>NFi5c5VUSU6JRWK=
NCI-SNU-1Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXMU41KSzVyPUOuOlk4OzVizszNM16w[3NCVkeHUh?=
BT-20NGraWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fnOGlEPTB;Mz62PVc6PSEQvF2=NXrpVm9KW0GQR1XS
LS-123NVOwVXlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfMTWM2OD1|Lke0Nlg1KM7:TR?=MkDIV2FPT0WU
8305CM3HCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\sOXRKSzVyPUOuO|U6OTFizszNMXXTRW5ITVJ?
OCUB-MMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XocGlEPTB;Mz63OlE5PyEQvF2=MnzXV2FPT0WU
KOSC-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnrTWM2OD1|LkizOFUyKM7:TR?=MnHmV2FPT0WU
NCI-H1693M1\yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mne2TWM2OD1|Lki0NVgyKM7:TR?=NF;LeZRUSU6JRWK=
TE-9MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTNwOESzPFIh|ryPNVHBVY9DW0GQR1XS
MV-4-11MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjsdHNQUUN3ME2zMlg4QTl2IN88US=>NWXlR|VxW0GQR1XS
GAMGMleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELhPIZKSzVyPUOuPVE{OTRizszNM3j0XnNCVkeHUh?=
KNS-62NXn1Rnd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTNwOUS3N|Eh|ryPMoDEV2FPT0WU
MC116M4jUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3P6RmlEPTB;Mz65OVQ5QSEQvF2=MlLXV2FPT0WU
647-VMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnGOmJoUUN3ME2zMlk5PDV{IN88US=>NH[yepBUSU6JRWK=
U-87-MGM3XQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLHZXpKSzVyPUSuNVA1QDFizszNNV:wUWpbW0GQR1XS
RPMI-8226MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M335RmlEPTB;ND6xNVY{OSEQvF2=Mn7kV2FPT0WU
SW1417MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH6zU3BKSzVyPUSuNVIyPDdizszNNYPBfnIzW0GQR1XS
LAMA-84MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTRwMUewNkDPxE1?NH7aSXRUSU6JRWK=
LS-513NF6zSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\QbFBKSzVyPUSuN|EzOTdizszNMWHTRW5ITVJ?
KLEMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnjfm9CUUN3ME20MlQxQDF7IN88US=>MVHTRW5ITVJ?
HCT-116M3[2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV[0cYtOUUN3ME20MlQyODB5IN88US=>M{XlZnNCVkeHUh?=
EPLC-272HMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4[5[2lEPTB;ND60NVU{OyEQvF2=NU\KXmZJW0GQR1XS
KS-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHqTWM2OD12LkWwPFg6KM7:TR?=MmDUV2FPT0WU
HT-1197M13vdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTRwNUK2Olkh|ryPNGXUUpVUSU6JRWK=
LCLC-97TM1Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWn5XJlmUUN3ME20MlU{Pjh4IN88US=>NX3wN45CW0GQR1XS
ES5NHf5WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPlfYZKSzVyPUSuPFM4OjNizszNMmW5V2FPT0WU
CTB-1MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M365fWlEPTB;ND64OFg5KM7:TR?=MlzkV2FPT0WU
HL-60M1e5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3kXppMUUN3ME20Mlg3PjFzIN88US=>MX3TRW5ITVJ?
VM-CUB-1NGKxNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTRwOE[4NVkh|ryPM1S1SXNCVkeHUh?=
MEG-01Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;LS2lEPTB;ND65PVQxOyEQvF2=NF3MSpFUSU6JRWK=
KYSE-520NFLrZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;lT5FKSzVyPUWuNlA5OzlizszNMVHTRW5ITVJ?
HuO-3N1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\MSmlWUUN3ME21MlI1ODR|IN88US=>NGXoZmpUSU6JRWK=
SW620NILJbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;3ZYZKSzVyPUWuNlQ6PjRizszNMYHTRW5ITVJ?
U031NVXieWdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTVwMkW0NlQh|ryPMkXtV2FPT0WU
TE-5NE\hNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTVwNEC4OUDPxE1?NXvaOZMyW0GQR1XS
NCI-H747NGDaeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWKyO3lvUUN3ME21MlQzPDd{IN88US=>MV\TRW5ITVJ?
MG-63MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPCWG1JUUN3ME21MlQ5PzZ{IN88US=>NV7xUldCW0GQR1XS
HC-1NGOydVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jlNmlEPTB;NT61NVg{QSEQvF2=M4fzfnNCVkeHUh?=
HCC2998MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTVwNUK2NVUh|ryPMkmyV2FPT0WU
NTERA-S-cl-D1NYLL[ZoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTVwNUS1N|ch|ryPNYLK[GV3W0GQR1XS
KINGS-1NXXZdIJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnK5TWM2OD13Lk[wPVQ1KM7:TR?=NYfINlcyW0GQR1XS
D-423MGNWnlbo9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:4[JBbUUN3ME21MlYyPzB3IN88US=>M1fje3NCVkeHUh?=
SW962NG\RWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljPTWM2OD13Lk[yNFMzKM7:TR?=NFPle|RUSU6JRWK=
LOXIMVIMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFz2eXBKSzVyPUWuOlM5PzNizszNMV3TRW5ITVJ?
LS-411NMmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTVwN{m0OFEh|ryPNGfFXJRUSU6JRWK=
NCI-H2291NGrifHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTVwOUi5OFMh|ryPNXm2PI92W0GQR1XS
A549MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInjWJpKSzVyPU[uNVI2PTNizszNNEfRd5pUSU6JRWK=
LS-1034NXGzUHFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;oTWM2OD14LkKwO|A3KM7:TR?=MUXTRW5ITVJ?
NB14MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;YTWM2OD14LkSzPFM3KM7:TR?=MY\TRW5ITVJ?
NCI-H1299NIfpVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTZwNkOxO|Eh|ryPMnXzV2FPT0WU
BT-549NEO5XoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfPPXVWUUN3ME22MlY3QDh7IN88US=>Mk[3V2FPT0WU
J-RT3-T3-5M12wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;KbWlEPTB;Nj64Olkh|ryPNUP6Tpp7W0GQR1XS
SW756NU\VTWhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjpU3BZUUN3ME22MlkyOTd4IN88US=>MlP0V2FPT0WU
DJM-1M1G3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYmxRZg6UUN3ME22MlkzODF{IN88US=>MnfDV2FPT0WU
GP5dNH3wXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTZwOUezPVQh|ryPNWq3T3kzW0GQR1XS
MOLT-4MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjrTWM2OD15LkCyNVM2KM7:TR?=NVjDXIZmW0GQR1XS
NCI-H28M325e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\PTWM2OD15LkG2OFA2KM7:TR?=MWjTRW5ITVJ?
MN-60Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTdwMkiwPFkh|ryPM3nZNHNCVkeHUh?=
RMG-INF\qbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\5[2lIUUN3ME23MlM6Ojl4IN88US=>MVrTRW5ITVJ?
COLO-800MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;3TWM2OD15LkSxOFQ3KM7:TR?=NIe1bGRUSU6JRWK=
DBM4PIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHf6fY9KSzVyPUeuOlExODVizszNMVvTRW5ITVJ?
Ca-SkiMmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHOPFJSUUN3ME23MlY1OjV7IN88US=>NH[2bI1USU6JRWK=
HELM3PEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTdwN{GyNFMh|ryPMnXLV2FPT0WU
NH-12M3HrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nIO2lEPTB;Nz63NlgxQCEQvF2=NFLYR3ZUSU6JRWK=
LB373-MEL-DM1nZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTVTWM2OD15Lke2O|cyKM7:TR?=MXHTRW5ITVJ?
SW900MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LnbGlEPTB;Nz64NlEzOSEQvF2=NFzzV2xUSU6JRWK=
JVM-3MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zxPWlEPTB;Nz64PVU6QSEQvF2=NUixNoNPW0GQR1XS
OAW-28MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;OTWM2OD15Lkm0OVc5KM7:TR?=MUfTRW5ITVJ?
KURAMOCHIM{WxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4f3TmlEPTB;Nz65OFgyOSEQvF2=NHra[|JUSU6JRWK=
BE-13MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYT0NGs2UUN3ME23Mlk5OTF{IN88US=>MnjtV2FPT0WU
VMRC-RCZM2TmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmq3TWM2OD16LkCxOlk4KM7:TR?=MkDVV2FPT0WU
NCI-H727NVq2XVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTkSIxqUUN3ME24MlExPDJizszNNWPVco1nW0GQR1XS
SW1710MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnq[IdDUUN3ME24MlE5PTF3IN88US=>MUnTRW5ITVJ?
D-502MGMoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRThwMkmyPFIh|ryPMUnTRW5ITVJ?
NCI-H1993NIfZcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRThwM{O2N|Eh|ryPM{\6cHNCVkeHUh?=
SCC-4MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWP5VnRLUUN3ME24MlQ1ODV7IN88US=>NGSyNZRUSU6JRWK=
HAL-01NYXQU3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\pcXhKSzVyPUiuOVE6OSEQvF2=MX;TRW5ITVJ?
GT3TKBMke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPVTWM2OD16Lk[3PVY1KM7:TR?=MnK4V2FPT0WU
SK-OV-3MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIqzb|BKSzVyPUiuO|E{OjlizszNM37yRXNCVkeHUh?=
COLO-829MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFT3ZmRKSzVyPUiuPFA6PzZizszNNF7K[3VUSU6JRWK=
OCI-AML2NFT3enlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTqTWM2OD16Lkm1OFgyKM7:TR?=NXHpWHhUW0GQR1XS
OS-RC-2NUDJSVdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3lPFJKSzVyPUmuNFIyQSEQvF2=MYHTRW5ITVJ?
BFTC-909MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjXTWM2OD17LkC2O|k6KM7:TR?=MWnTRW5ITVJ?
EW-11M1jJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTlwMUe2OVMh|ryPM{TQU3NCVkeHUh?=
HCE-4NUS4VIZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLEfWJKSzVyPUmuNlE2PThizszNMX\TRW5ITVJ?
BALL-1NH\RW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HWOWlEPTB;OT6yNVkxPyEQvF2=NWXGeHc5W0GQR1XS
SF539MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4[2WGlEPTB;OT6yN|U3OiEQvF2=Mn\PV2FPT0WU
CAMA-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3ETWM2OD17LkK4NVI5KM7:TR?=NUCxTXpwW0GQR1XS
C32M2jDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1[zPWlEPTB;OT6zN|A3PCEQvF2=NIrFUYxUSU6JRWK=
NCI-H1703NFHrVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvoSVVqUUN3ME25MlM1Ozd3IN88US=>MWjTRW5ITVJ?
NCI-H1650NE\HU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjLTWM2OD17Lk[wPVQ3KM7:TR?=MnXPV2FPT0WU
NCI-H1563NITKXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHX1[ZRKSzVyPUmuO|YxOzFizszNMnLUV2FPT0WU
CAL-85-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jFWGlEPTB;OT64O|M5OyEQvF2=MYDTRW5ITVJ?
UM-UC-3M1fnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXQTWM2OD17Lkm1NFMh|ryPNGLIXFhUSU6JRWK=
BxPC-3MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LacmlEPTB;MUCuNFk4OiEQvF2=M33VU3NCVkeHUh?=
MHH-PREB-1M4XFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTFyLkG5PVkh|ryPMnnnV2FPT0WU
DELNUnBeGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHLXZh4UUN3ME2xNE4{QTR4IN88US=>MmTuV2FPT0WU
HuCCT1MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofHTWM2OD1zMD62NFM{KM7:TR?=NVnmPYJ6W0GQR1XS
OVCAR-4NIfZcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nhWmlEPTB;MUCuPFg{PSEQvF2=MXrTRW5ITVJ?
CAL-72NFzGfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrwUWhKUUN3ME2xNE46OzlzIN88US=>NFjsfYlUSU6JRWK=
HCC1954NWH6RotMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTFzLkC3OVQh|ryPMVHTRW5ITVJ?
EFO-21MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfwdmtUUUN3ME2xNU4yODR3IN88US=>NYnISmtkW0GQR1XS
FTC-133M2nkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLoTWM2OD1zMT6xOFA4KM7:TR?=NUT0[mZuW0GQR1XS
SK-MEL-24M4XQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTFzLkKzOlYh|ryPNWTQXJhEW0GQR1XS
UACC-62MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTFzLkKzOlgh|ryPMY\TRW5ITVJ?
NCI-H650M2nqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NICxd3pKSzVyPUGxMlI1OThizszNM2rRcHNCVkeHUh?=
ALL-PONHPFcGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzaTHBKSzVyPUGxMlI2OTJizszNNHnZSlJUSU6JRWK=
T84MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnRWGV{UUN3ME2xNU4{QTB5IN88US=>MkjnV2FPT0WU
IST-MEL1M2PRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;5Wm9lUUN3ME2xNU41PTV7IN88US=>M2DXOHNCVkeHUh?=
SW626MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnmeodOUUN3ME2xNU42PzV3IN88US=>M2TQenNCVkeHUh?=
RPMI-2650M1vQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorxTWM2OD1zMT61PFg2KM7:TR?=MkW1V2FPT0WU
MC-IXCNG[2SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLVTWM2OD1zMT62O|I5KM7:TR?=MlzXV2FPT0WU
HOP-62MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLxTWM2OD1zMT62O|Y1KM7:TR?=NVe1RXA6W0GQR1XS
NOS-1MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3viNWlEPTB;MUGuO|ExQSEQvF2=MlfIV2FPT0WU
SW1573NWXWSY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjmO|lKSzVyPUGxMlczQTVizszNM3nMT3NCVkeHUh?=
WM-115M{jo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGj4RW1KSzVyPUGxMlc2QDhizszNMoG5V2FPT0WU
HuO9MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTFzLki3O|Qh|ryPM4m4b3NCVkeHUh?=
YAPCNEnTfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljTTWM2OD1zMT65NlU6KM7:TR?=NVXYTpN[W0GQR1XS
MDA-MB-453NFnTcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTFzLkm1NVUh|ryPMlX1V2FPT0WU
NCI-H596NUPWfHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTF{LkCzOlkh|ryPNH\xTVVUSU6JRWK=
A172MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPCTWM2OD1zMj6wO|k5KM7:TR?=NFzjS5dUSU6JRWK=
RS4-11M1KyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH61ZnBKSzVyPUGyMlE4OjVizszNNVL0[4lmW0GQR1XS
HCC1937MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkf4TWM2OD1zMj63OVY1KM7:TR?=MnrRV2FPT0WU
SW837NHHkR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTF{LkmwNlgh|ryPNEC1ZodUSU6JRWK=
NMC-G1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XUXmlEPTB;MUKuPVI{PCEQvF2=NEfwdohUSU6JRWK=
PFSK-1M3fUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\HOmlEPTB;MUOuNFYh|ryPMlztV2FPT0WU
DBTRG-05MGMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYqwNoN2UUN3ME2xN{4xPjN{IN88US=>NEfmNItUSU6JRWK=
SK-UT-1NWLJVJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTXTWM2OD1zMz6xNFg{KM7:TR?=Ml\SV2FPT0WU
OVCAR-5NGXJUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIL5ZpdKSzVyPUGzMlE2QTNizszNNHT2SohUSU6JRWK=
8505CMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjHTWM2OD1zMz6yNFY4KM7:TR?=MV;TRW5ITVJ?
SK-MEL-1NUnaRlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTBTWM2OD1zMz63NVM2KM7:TR?=MkTKV2FPT0WU
LK-2MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnHTWM2OD1zMz63OlM6KM7:TR?=M{HMVHNCVkeHUh?=
OE33NEmzWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTZW5lMUUN3ME2xN{44QDZizszNMmj1V2FPT0WU
Ramos-2G6-4C10M1nlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXPbIlKSzVyPUG0MlAzODJizszNM2TFSXNCVkeHUh?=
EW-13M1fTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFywe4FKSzVyPUG0MlA{PTJizszNM2jKXHNCVkeHUh?=
NCI-H1793MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnnPIhSUUN3ME2xOE4zODh5IN88US=>M3TzWXNCVkeHUh?=
BHT-101M4PVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2eySmlEPTB;MUSuNlQyKM7:TR?=MmW0V2FPT0WU
RKONXjpTGxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DvTGlEPTB;MUSuOVA4PSEQvF2=Mn3aV2FPT0WU
NEC8MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnmcW8zUUN3ME2xOE42PDd{IN88US=>MnL2V2FPT0WU
PANC-10-05NVn4U4FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmD2TWM2OD1zND62NlQ4KM7:TR?=MYXTRW5ITVJ?
NCI-H2030NXfnSlVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF2Lk[0OFgh|ryPM{ThNXNCVkeHUh?=
C2BBe1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDUVFBbUUN3ME2xOE44PjRizszNM1zZZnNCVkeHUh?=
EM-2MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUW5c5psUUN3ME2xOE45PTd4IN88US=>MYnTRW5ITVJ?
HCC1395NIL0V3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTF2LkmzN|gh|ryPNGO3ZmpUSU6JRWK=
A2058NYrBdZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXuSHJKSzVyPUG1MlA1ODlizszNNXzDWYl3W0GQR1XS
SW1463NYPUbVIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTF3LkC0PFUh|ryPM{n2OHNCVkeHUh?=
J82MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHz4fJdKSzVyPUG1MlA2PyEQvF2=NVS4XGZ1W0GQR1XS
CAL-120MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHVWo02UUN3ME2xOU4yPDR5IN88US=>NIjCXXVUSU6JRWK=
COLO-824M2jtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPBTWM2OD1zNT6xOVc6KM7:TR?=NVTHTYk6W0GQR1XS
LNCaP-Clone-FGCNYjJXWFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHMTWM2OD1zNT60NlQ5KM7:TR?=M4fVSXNCVkeHUh?=
CP66-MELNV63dIxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2C0UGlEPTB;MUWuOFY5QCEQvF2=NWrpbmZ7W0GQR1XS
OC-314MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmD6TWM2OD1zNT60O|E1KM7:TR?=M1TCenNCVkeHUh?=
OVCAR-8M{LVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTF3Lki4OlEh|ryPMVPTRW5ITVJ?
MFE-280M4XUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PoOGlEPTB;MU[uNFQ5QCEQvF2=Mo\ZV2FPT0WU
MHH-NB-11M2j3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTF4LkC4N|kh|ryPM2rPXnNCVkeHUh?=
SW1990MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTF4LkG3OVUh|ryPMUfTRW5ITVJ?
U-266MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjDTWM2OD1zNj6yNlk6KM7:TR?=NGnUPXVUSU6JRWK=
MFM-223MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33YU2lEPTB;MU[uN|k3PSEQvF2=NGDvVFNUSU6JRWK=
L-363M4TNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzrUFNbUUN3ME2xOk41PTd5IN88US=>MY\TRW5ITVJ?
MCF7NHuzUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTuW4pKSzVyPUG2MlQ4OjNizszNNY\LVGp3W0GQR1XS
SK-MEL-3MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PyZ2lEPTB;MU[uOFc5PyEQvF2=MUfTRW5ITVJ?
HHMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mly4TWM2OD1zNj61NVYzKM7:TR?=M1TyenNCVkeHUh?=
no-10M3LsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXmTWM2OD1zNj62N|Q{KM7:TR?=M4PLW3NCVkeHUh?=
HuP-T3M3HqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTF4Lk[1O|Yh|ryPM4X6SHNCVkeHUh?=
QIMR-WILM1TkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYL0W5JGUUN3ME2xOk44OTB3IN88US=>MVHTRW5ITVJ?
NCI-H1092M2nsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\5WWlEPTB;MU[uPFMyPiEQvF2=NInXbFZUSU6JRWK=
MZ2-MELNFXmWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\rTWM2OD1zNj64OFA{KM7:TR?=MX\TRW5ITVJ?
ES3MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTZdJZvUUN3ME2xOk46OTN2IN88US=>NVv0b4dnW0GQR1XS
COLO-684MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\WO4JsUUN3ME2xOk46PDd5IN88US=>MXnTRW5ITVJ?
NCI-H661NXfxWo9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTF4Lkm2PVQh|ryPNV;Ye5RzW0GQR1XS
CP50-MEL-BM{Dz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUO4fGEzUUN3ME2xO{4xOzR|IN88US=>NVfmNHA6W0GQR1XS
NCI-H2405MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHy4XnNKSzVyPUG3MlE6PzRizszNNVzmPIl6W0GQR1XS
U-2-OSM3XacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTqTWM2OD1zNz61N|A4KM7:TR?=M33ZT3NCVkeHUh?=
RERF-LC-MSNHrY[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXV[I9KSzVyPUG3MlU2ODhizszNNGLHe3NUSU6JRWK=
NCI-H2342NF3ZV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rFZWlEPTB;MUeuOVU4KM7:TR?=NVPaZ|JnW0GQR1XS
ES8MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHT4U2hKSzVyPUG3MlYxQDdizszNM2m3dnNCVkeHUh?=
MOLT-16NXvEWlJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHryO3lKSzVyPUG3Mlg6OzRizszNM1PR[XNCVkeHUh?=
RH-18M4[3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnqTWM2OD1zOD6wNFM2KM7:TR?=NIr1bnZUSU6JRWK=
D-283MEDNX\nemI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTF6LkCwPFgh|ryPNYm4T5AzW0GQR1XS
RCC10RGBMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLnTWM2OD1zOD6wOVU6KM7:TR?=M1OwfHNCVkeHUh?=
NCI-H1437NGLRO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFn4ToRKSzVyPUG4MlE3PDFizszNNGn1O3pUSU6JRWK=
SW982NGrwUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWG0WpZ4UUN3ME2xPE4zPjdzIN88US=>M1u1[nNCVkeHUh?=
IST-MES1M1;rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnqTWM2OD1zOD60OFI5KM7:TR?=NVf4WIpRW0GQR1XS
A704NWT5[ms5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF6LkS3OVMh|ryPM1:0Z3NCVkeHUh?=
ESS-1M37jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLNTWM2OD1zOD61NlA2KM7:TR?=NVOxRnA5W0GQR1XS
SCHMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFz5XohKSzVyPUG4MlY1PTZizszNM1LMSnNCVkeHUh?=
COLO-320-HSRNUezT2pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTF6Lke0OkDPxE1?NIrGXoxUSU6JRWK=
Mo-TMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zKeGlEPTB;MUiuPFIxPCEQvF2=NYPoeZVkW0GQR1XS
Saos-2NG\HSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2m1WWlEPTB;MUmuNVE3OiEQvF2=NEXYe2pUSU6JRWK=
SW684MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvYcY1KSzVyPUG5MlE{OjZizszNNIK1XnpUSU6JRWK=
KMOE-2NIrHUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\2TWM2OD1zOT6yNlQzKM7:TR?=NVL0TG1uW0GQR1XS
MMAC-SFM4f1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml[wTWM2OD1zOT6yOlA4KM7:TR?=NFi4[oJUSU6JRWK=
JARM4r3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrSTWM2OD1zOT6yPVkh|ryPM2LV[3NCVkeHUh?=
SK-MEL-28NWPRVVM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTF7LkOzOlMh|ryPNIrP[2NUSU6JRWK=
KNS-81-FDMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvm[o41UUN3ME2xPU42PDZ6IN88US=>NV\aWZZ5W0GQR1XS
ES7NH3pem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYOwUHJkUUN3ME2xPU43Ojl{IN88US=>NWrESGJwW0GQR1XS
AsPC-1M{XnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\zXGlEPTB;MUmuOlQ4OSEQvF2=M{js[HNCVkeHUh?=
NCI-H1155NGDnfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTF7LkeyN|gh|ryPMnPFV2FPT0WU
KYSE-510NHfSSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nJcmlEPTB;MUmuPFc1QCEQvF2=NYf0cG5UW0GQR1XS
ES1NH[xXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTF7LkmyNVMh|ryPMVvTRW5ITVJ?
PC-3M{XwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLHTWM2OD1zOT65OlA1KM7:TR?=Mmf5V2FPT0WU
GCTMmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH31elJKSzVyPUKwMlMxOjZizszNNYD4fZZoW0GQR1XS
KARPAS-299MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTlTWM2OD1{MD6zOFIzKM7:TR?=NV74OJRpW0GQR1XS
DOHH-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXlUno5UUN3ME2yNE42PDZ|IN88US=>MnvaV2FPT0WU
COLO-741M4P2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPITFNKSzVyPUKwMlY3KM7:TR?=NEfoc3NUSU6JRWK=
NCI-H1395M2Lvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{H6[2lEPTB;MkCuOlY6PyEQvF2=MXzTRW5ITVJ?
HCC1187MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\sTWM2OD1{MD62O|M1KM7:TR?=NGC0Xm5USU6JRWK=
BeckerMnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTJyLkeyNFEh|ryPM{nRNHNCVkeHUh?=
LU-134-ANFLiXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTJzLkGwNlYh|ryPM2HlenNCVkeHUh?=
MKN45M1nkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDDTWM2OD1{MT6xOVUyKM7:TR?=NFXR[GRUSU6JRWK=
LC-2-adMnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPMZW5KSzVyPUKxMlI4OjlizszNNE\ydYhUSU6JRWK=
EW-24NHW0SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nIVmlEPTB;MkGuN|k1PSEQvF2=NUPWZ2p4W0GQR1XS
SK-N-ASMmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLWb4tKSzVyPUKxMlgzPzZizszNNVHHb4xZW0GQR1XS
NCI-H2052NVvkW4lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTJzLki5OlMh|ryPNXGzT|hYW0GQR1XS
A4-FukNITLRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jy[mlEPTB;MkKuNVQyQSEQvF2=MnL1V2FPT0WU
NB10NIfBdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPse4lKSzVyPUKyMlI{PzFizszNMY\TRW5ITVJ?
CHP-212MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\rO2lEPTB;MkKuN|IzOiEQvF2=MX;TRW5ITVJ?
KM12M13PfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJ{LkO1OkDPxE1?MUPTRW5ITVJ?
JEG-3M3\ld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknVTWM2OD1{Mj6zO|gh|ryPNWC2eZlFW0GQR1XS
LN-405Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTJ{LkW5NVMh|ryPNV\GO21RW0GQR1XS
HCT-15MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LpPWlEPTB;MkKuO|Q1OSEQvF2=MWPTRW5ITVJ?
MLMAM{L0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3hV5ZEUUN3ME2yNk44PDdizszNMnvjV2FPT0WU
GI-1NWm0TVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXPfVhKSzVyPUKyMlc3PThizszNNGG5TVdUSU6JRWK=
RT-112NYKw[GRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnu2TWM2OD1{Mj64OlE3KM7:TR?=M{XqS3NCVkeHUh?=
MPP-89MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTJ{Lki2OlEh|ryPM1;5T3NCVkeHUh?=
A3-KAWNFPkflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTMTWM2OD1{Mz6xNFA{KM7:TR?=MWLTRW5ITVJ?
KALS-1MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MneyTWM2OD1{Mz6xOFE1KM7:TR?=M4\BbHNCVkeHUh?=
SF126M4jFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPKSGVrUUN3ME2yN{43QTJ2IN88US=>NIr0UnpUSU6JRWK=
SiHaM170VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jydGlEPTB;MkOuPVMzPyEQvF2=NIX3NXRUSU6JRWK=
MDA-MB-415NY\FU5VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJ|Lkm0PVkh|ryPNGS3cZFUSU6JRWK=
DaoyNFLsWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTJ2LkGyOkDPxE1?M3n4SHNCVkeHUh?=
COR-L23NEnE[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJ2LkG3Olch|ryPM3G0UHNCVkeHUh?=
KG-1NUC3dFZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnLTWM2OD1{ND6xPVI5KM7:TR?=MYjTRW5ITVJ?
L-428MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHNXJVKSzVyPUK0MlU4QTFizszNNIr1[WZUSU6JRWK=
NCI-H520NGK0[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M324PGlEPTB;MkSuPFg3OSEQvF2=M2LadHNCVkeHUh?=
COLO-792NInGZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LLR2lEPTB;MkWuNlc{OiEQvF2=NF\YVlZUSU6JRWK=
NB12NHzLeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3P2N2lEPTB;MkWuNlk1PyEQvF2=NW\2[FdRW0GQR1XS
GAKM2HibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYT6RZduUUN3ME2yOU4zQTZ|IN88US=>M4izfXNCVkeHUh?=
SW780MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjTOpB3UUN3ME2yOU4{OjZ2IN88US=>M4XQO3NCVkeHUh?=
GB-1NILWXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjaV3FKSzVyPUK1MlQxPjlizszNNUfUeI9xW0GQR1XS
P12-ICHIKAWAMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nBWmlEPTB;MkWuOFc5PSEQvF2=Mm\rV2FPT0WU
NCI-H1651NHqyfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{i3XmlEPTB;MkWuOVk4KM7:TR?=MnHvV2FPT0WU
KE-37MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTJ3LkezNVUh|ryPNYOwPII3W0GQR1XS
CCRF-CEMMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTJ3Lkm2O{DPxE1?NHPoO2RUSU6JRWK=
SF295Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\nTWM2OD1{Nj6wOFI2KM7:TR?=M1H3eXNCVkeHUh?=
G-361M2TITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIe0[otKSzVyPUK2MlExOjdizszNMnvTV2FPT0WU
HOP-92MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjVem1KSzVyPUK2MlEzOjZizszNNFXWWWdUSU6JRWK=
UMC-11NVjPTnBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TZZWlEPTB;Mk[uOFUyPCEQvF2=MWDTRW5ITVJ?
IST-SL1NYTIUXFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\xeJV3UUN3ME2yOk43PTlzIN88US=>MV7TRW5ITVJ?
TE-11MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\tSGlEPTB;Mk[uO|c2OiEQvF2=NWHzfGFHW0GQR1XS
NCI-H1304M2ToZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLscoVlUUN3ME2yOk46OTB6IN88US=>M1HlOXNCVkeHUh?=
SJSA-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnZTWM2OD1{Nz6wNVc3KM7:TR?=NVLWPZNtW0GQR1XS
BCPAPM3jlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPacHZKSzVyPUK3MlE{PyEQvF2=M2[3THNCVkeHUh?=
HTC-C3NInNblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTJ5LkK1OlEh|ryPMV\TRW5ITVJ?
EW-16NILSNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{j1e2lEPTB;MkeuNlk1PyEQvF2=MUHTRW5ITVJ?
HT-144NGO1WWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTJ5LkSwN|Ih|ryPMVLTRW5ITVJ?
MHH-ES-1NXnsW5VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\PdYtYUUN3ME2yO{41PDR5IN88US=>M{\RXnNCVkeHUh?=
T98GNYXTcHN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TJRWlEPTB;MkeuOVg1PiEQvF2=Mnv4V2FPT0WU
RPMI-8866NG\ifWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVP4SWRnUUN3ME2yO{44PTZ{IN88US=>NVO2cVBZW0GQR1XS
BENM2T4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XyUmlEPTB;MkeuPFUyPyEQvF2=NEHVfI9USU6JRWK=
MDA-MB-231NVHjVmhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mni3TWM2OD1{OD6yO|k2KM7:TR?=NH24VXRUSU6JRWK=
HuH-7MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPNWWVKSzVyPUK4MlQxOjhizszNMnzrV2FPT0WU
SK-N-FINX7pXZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfVTGVjUUN3ME2yPE41OzNizszNMkHPV2FPT0WU
AN3-CAM1XxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;xcoZKSzVyPUK4MlQ{QTVizszNM1jsc3NCVkeHUh?=
EGI-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHaTWM2OD1{OD61PVI5KM7:TR?=MWDTRW5ITVJ?
697NWjxbXI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHlTWM2OD1{OD62N|MyKM7:TR?=M{fmbXNCVkeHUh?=
TCCSUPMkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTJ6Lk[0NVgh|ryPM1q4SnNCVkeHUh?=
GR-STMkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vs[GlEPTB;MkiuOlY6PiEQvF2=MnjHV2FPT0WU
SK-N-DZMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTJ6Lk[4PFUh|ryPMk\vV2FPT0WU
MIA-PaCa-2NHG4PYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XDXWlEPTB;MkiuO|k2QSEQvF2=NYDjWnVsW0GQR1XS
IGR-1NXKxdHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJ6Lki4O|Qh|ryPNXPqW4JTW0GQR1XS
BFTC-905NFjP[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTJ7LkK3NFUh|ryPM2XTOXNCVkeHUh?=
NCI-H1581M333d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHoVJYyUUN3ME2yPU4{OTR3IN88US=>MWnTRW5ITVJ?
RDMmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjsVXNKSzVyPUK5MlUzOzNizszNMWnTRW5ITVJ?
SF268M{TCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LUZ2lEPTB;MkmuOVk{OSEQvF2=NVPwbJRZW0GQR1XS
SHP-77M3fOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTJ7Lk[xPFIh|ryPNFTEdlRUSU6JRWK=
D-566MGMn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTJ7LkmzPVMh|ryPNYroc5VPW0GQR1XS
TGBC1TKBM{\C[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DZc2lEPTB;M{CuNVI{QCEQvF2=MYrTRW5ITVJ?
MEL-HOMkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PrSGlEPTB;M{CuNVQzOyEQvF2=NV\hNmNSW0GQR1XS
SJRH30NXPndWJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4G1T2lEPTB;M{CuNlExQCEQvF2=NHnWUHRUSU6JRWK=
D-336MGMn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXsRpAyUUN3ME2zNE4zQDl{IN88US=>MWfTRW5ITVJ?
C3AM1jvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{D4R2lEPTB;M{CuNlkzPyEQvF2=NGPFT2dUSU6JRWK=
Calu-6M1nJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPXOVRKSzVyPUOwMlI6PjNizszNNHH4RXhUSU6JRWK=
MZ1-PCMlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTNyLkO5N{DPxE1?NIPEfoFUSU6JRWK=
KYSE-70MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXENW5wUUN3ME2zNE42OTF2IN88US=>NXzjOFhIW0GQR1XS
CAPAN-1NFn5fVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTNyLkWxPFEh|ryPNH;UdmFUSU6JRWK=
DK-MGMkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjINItKSzVyPUOwMlU1PTZizszNNUfjOXRqW0GQR1XS
SK-HEP-1M3vqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mke1TWM2OD1|MD62N|I3KM7:TR?=MYrTRW5ITVJ?
MS-1Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnwTWM2OD1|MD64PFg6KM7:TR?=MY\TRW5ITVJ?
GI-ME-NNUTLT45HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHLTWM2OD1|MT6wOVcyKM7:TR?=M4i0SnNCVkeHUh?=
NCI-H510AM4DucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3xWmRKUUN3ME2zNU41ODB4IN88US=>MoHHV2FPT0WU
NB17MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jFRWlEPTB;M{GuOVE5PSEQvF2=M4SyTnNCVkeHUh?=
639-VM4HPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;SeWlEPTB;M{GuOVI1OyEQvF2=MkewV2FPT0WU
CAL-51MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;0TWM2OD1|MT61OlY4KM7:TR?=MXzTRW5ITVJ?
HGC-27M2LZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXj4dZhsUUN3ME2zNU42QDd|IN88US=>M4jHRXNCVkeHUh?=
GOTOM1jodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXIUFJKSzVyPUOxMlg2ODZizszNMojWV2FPT0WU
ChaGo-K-1MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnwTWM2OD1|Mj6wNFch|ryPMXLTRW5ITVJ?
RO82-W-1NVHIXGkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7NTWM2OD1|Mj6xOlA1KM7:TR?=MlPLV2FPT0WU
SH-4MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmH1TWM2OD1|Mj6xPFU5KM7:TR?=Ml:yV2FPT0WU
A204NXXp[lVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37HNWlEPTB;M{KuOVA3QSEQvF2=NVrDVI9zW0GQR1XS
DMS-273NHTaOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPnTWM2OD1|Mj61N|IzKM7:TR?=MnHyV2FPT0WU
KGNMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTN{Lk[zN{DPxE1?MmLCV2FPT0WU
SK-MEL-2M4PCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XTSGlEPTB;M{KuOlUzPyEQvF2=NXPpdZVoW0GQR1XS
NCI-H2228M{DE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUmwfXE3UUN3ME2zNk43PjB{IN88US=>MoH0V2FPT0WU
MKN28M4rIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjzTWM2OD1|Mj63PFM5KM7:TR?=NI\S[HJUSU6JRWK=
H-EMC-SSM1TZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\ofHFKSzVyPUOyMlk3PzhizszNNWC4b4NnW0GQR1XS
ATN-1MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTN|LkG0NVYh|ryPMV7TRW5ITVJ?
D-263MGM13nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTN|LkizO|gh|ryPNXXrcnFXW0GQR1XS
LU-135MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mof0TWM2OD1|Mz64PFI6KM7:TR?=M1zQ[HNCVkeHUh?=
C8166MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYT5XlR6UUN3ME2zN{45QDV2IN88US=>NH3rdXFUSU6JRWK=
T-24NEHCSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIq0fW5KSzVyPUO0MlAzODVizszNNF[2d|RUSU6JRWK=
MewoMmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{P5[2lEPTB;M{SuNVM1QSEQvF2=NFPmPGZUSU6JRWK=
22RV1NI[5XXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTN2LkG3OVQh|ryPM1W1TnNCVkeHUh?=
KM-H2M{X3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWSze2VIUUN3ME2zOE4yPzd7IN88US=>NFj5bJVUSU6JRWK=
NCI-H2122M2HwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDLfJlKSzVyPUO0MlM1PzFizszNNIjvW2pUSU6JRWK=
ABC-1MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjGdlRHUUN3ME2zOE4{Pjl|IN88US=>M1P0eXNCVkeHUh?=
NCI-H1355NWO1T4FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPxTWM2OD1|ND6zPFg6KM7:TR?=NHHHVG1USU6JRWK=
NOMO-1NYTa[4lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPPTWM2OD1|ND61O|A{KM7:TR?=MmKxV2FPT0WU
MZ7-melNHPNUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HtT2lEPTB;M{SuOlQ5PyEQvF2=M4CzUnNCVkeHUh?=
NCI-H810NGfKVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fLZWlEPTB;M{SuO|I4QCEQvF2=M4C3OHNCVkeHUh?=
D-392MGNWH5dolUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnNSXVKSzVyPUO1MlA2PjVizszNNYfJS25QW0GQR1XS
LB771-HNCM3jmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFflRWtKSzVyPUO1MlE3PThizszNNXXlNmJ6W0GQR1XS
COLO-679MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTN3LkO4PEDPxE1?M4fPcXNCVkeHUh?=
SK-PN-DWMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;VS5VKSzVyPUO1MlQ{PjlizszNMn;lV2FPT0WU
VA-ES-BJMnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml[1TWM2OD1|NT60OlQ6KM7:TR?=NXPKU493W0GQR1XS
KNS-42NI\j[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTN3LkW4NlYh|ryPMlLJV2FPT0WU
RVH-421MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3u0VWlEPTB;M{WuO|Y1PSEQvF2=NGTv[|dUSU6JRWK=
P30-OHKM{K1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLXUGE6UUN3ME2zOU45PzV{IN88US=>NHnad|RUSU6JRWK=
G-402MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXOdGdKSzVyPUO1Mlk5PjdizszNMVPTRW5ITVJ?
S-117NFnNcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTN4LkOwNFgh|ryPMnvUV2FPT0WU
RXF393NWfGellxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTKeFVKSzVyPUO2MlM4QDVizszNM{j5OHNCVkeHUh?=
LCLC-103HM1;6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LydGlEPTB;M{[uO|gxOyEQvF2=MnjOV2FPT0WU
U-118-MGMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XJcmlEPTB;M{[uPFg1PyEQvF2=MWTTRW5ITVJ?
8-MG-BAM2fkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTN4Lkm0PFMh|ryPNWLk[IlqW0GQR1XS
MFH-inoMojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTN5LkOzO|Eh|ryPMVnTRW5ITVJ?
NCI-H23NF65bHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfsUGxEUUN3ME2zO{41OTl4IN88US=>NE\5dWVUSU6JRWK=
NCI-H446NF33VoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3z3XGlEPTB;M{euOFg3OiEQvF2=M{TRd3NCVkeHUh?=
LU-99AMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mki3TWM2OD1|Nz61O|MyKM7:TR?=NVLr[45sW0GQR1XS
KP-N-YNM1X4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHxfGxnUUN3ME2zO{43OTl3IN88US=>MnizV2FPT0WU
SCC-9MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTN5Lke4N|gh|ryPMWXTRW5ITVJ?
EFM-19MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHlT2dKSzVyPUO3Mlc6PjdizszNNHPrU3FUSU6JRWK=
A427M2Xle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nEU2lEPTB;M{euPVExPyEQvF2=MVLTRW5ITVJ?
LB831-BLCMkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rud2lEPTB;M{iuOlA{QSEQvF2=MWDTRW5ITVJ?
HOSM3[1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7ITWM2OD1|OT62Nlc{KM7:TR?=M4DvZXNCVkeHUh?=
LAN-6M4mwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\q[2lEPTB;NECuNFEyOiEQvF2=M2WyRnNCVkeHUh?=
U251M1HCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHHXmNHUUN3ME20NE41ODV2IN88US=>M3LWc3NCVkeHUh?=
SNU-387M3XPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDJZZNjUUN3ME20NE41PTV|IN88US=>M2i1TnNCVkeHUh?=
DMS-79NX36eGZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrwWVJ2UUN3ME20NE42QDh7IN88US=>MYLTRW5ITVJ?
SK-LU-1NX3uWJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHYOXd4UUN3ME20NE43PTZ6IN88US=>NYnFPZBTW0GQR1XS
HTNVT1OHZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3ETWM2OD12MD62OlM6KM7:TR?=NH7iO4FUSU6JRWK=
KP-N-YSNWP6WHIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGG4W3RKSzVyPUSwMlY4PjhizszNNIfmNYZUSU6JRWK=
DMS-114MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jpRmlEPTB;NECuPFM4PCEQvF2=NFvYO3dUSU6JRWK=
HUTU-80MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnIR45LUUN3ME20NU4xPTZ7IN88US=>NUnVcpl5W0GQR1XS
ONS-76NF\MU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PXSmlEPTB;NEGuOFcxQSEQvF2=MYTTRW5ITVJ?
A673MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXP1PW91UUN3ME20NU42OTV5IN88US=>M{XlZXNCVkeHUh?=
HPAF-IIMo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml6zTWM2OD12MT62O|A6KM7:TR?=NWfuUZRTW0GQR1XS
UACC-257NXG4U2l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGn3[3ZKSzVyPUSxMlc{PjlizszNMVLTRW5ITVJ?
EW-22NYC2ZmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTRzLki2PVch|ryPM3Tw[3NCVkeHUh?=
NCI-H1755M1\nR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnMTWM2OD12MT64O|I2KM7:TR?=M161dXNCVkeHUh?=
KYSE-150NXzxWXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVT6W|A1UUN3ME20Nk4yPzh{IN88US=>Mn23V2FPT0WU
CGTH-W-1M3P1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTR{LkS5OVUh|ryPM4S3cXNCVkeHUh?=
NB13NWfheHAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHrSYhzUUN3ME20Nk43OjF5IN88US=>MWTTRW5ITVJ?
SW872NVv0V49qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjnTWM2OD12Mj62N|MyKM7:TR?=NWP2cmVTW0GQR1XS
KP-4NXflPId1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDZe5dKSzVyPUSyMlg5OzJizszNM2XzUnNCVkeHUh?=
HCC38MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTR{Lkm2NVgh|ryPNHG3O3ZUSU6JRWK=
BB49-HNCNULUZ|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fLemlEPTB;NEOuNlM2PiEQvF2=NIfGS4tUSU6JRWK=
CAL-62NFy4SmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHWTWM2OD12Mz60NFI5KM7:TR?=NVHE[odNW0GQR1XS
NCI-H2029MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rXRWlEPTB;NEOuOVU5OSEQvF2=M3vsWnNCVkeHUh?=
M14MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;LVmlEPTB;NESuNVM{OiEQvF2=M2jBXnNCVkeHUh?=
COLO-680NNY\yenhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDHXIVKSzVyPUS0MlM{QSEQvF2=M4OxenNCVkeHUh?=
Hs-578-TMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTR3LkCyPVQh|ryPMl3BV2FPT0WU
MSTO-211HM3j4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDoUWVKSzVyPUS1Mlk1QDJizszNNEfN[4hUSU6JRWK=
EW-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojRTWM2OD12NT65Olg6KM7:TR?=NVTBd4FPW0GQR1XS
SW948NVfmfWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PxbGlEPTB;NE[uOFQ3OiEQvF2=NE\IbGJUSU6JRWK=
NCI-H460MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTlOWtKSzVyPUS2MlUzOyEQvF2=NIDKTWpUSU6JRWK=
CAS-1NVj3Oll1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vsW2lEPTB;NE[uO|cxOSEQvF2=MkfsV2FPT0WU
TGBC11TKBMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfhbVZQUUN3ME20O{4yPzd5IN88US=>M3rIbnNCVkeHUh?=
HD-MY-ZNI[4c3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLpWmNKSzVyPUS4Mlc5PiEQvF2=MV7TRW5ITVJ?
NCI-H226NF\XUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;nSWtzUUN3ME20PU44Pzh3IN88US=>NFP1ToFUSU6JRWK=
PA-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\BTWM2OD12OT64N|M2KM7:TR?=NUL5dmdKW0GQR1XS
LB2518-MELM1HtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHnTWM2OD12OT64O|I{KM7:TR?=M1;TVHNCVkeHUh?=
A101DNFfkcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTR7Lkm0NlUh|ryPM{jKeHNCVkeHUh?=
NCI-H2087MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Xk[2lEPTB;NEmuPVY5OiEQvF2=MXfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02501603 Recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University July 2016 Phase 2
NCT02795156 Not yet recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boe  ...more SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer July 2016 Phase 2
NCT02780687 Recruiting Urologic Neoplasms Boehringer Ingelheim June 2016 Phase 2
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose+0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Frequently Asked Questions

  • Question 1
    What’s the recommendation about reconstitution of the compound for in vivo animal study?

    Answer: For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) ic50 | Afatinib (BIBW2992) price | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) solubility dmso | Afatinib (BIBW2992) purchase | Afatinib (BIBW2992) manufacturer | Afatinib (BIBW2992) research buy | Afatinib (BIBW2992) order | Afatinib (BIBW2992) mouse | Afatinib (BIBW2992) chemical structure | Afatinib (BIBW2992) mw | Afatinib (BIBW2992) molecular weight | Afatinib (BIBW2992) datasheet | Afatinib (BIBW2992) supplier | Afatinib (BIBW2992) in vitro | Afatinib (BIBW2992) cell line | Afatinib (BIBW2992) concentration | Afatinib (BIBW2992) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us